{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:54:01Z","timestamp":1781870041218,"version":"3.54.5"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To evaluate the safety and efficacy of high-dose dual therapy (HDDT) for\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H. pylori)<\/jats:italic>\n                      eradication in patients with varying degrees of metabolic associated fatty liver disease (MAFLD)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 91 patients diagnosed with MAFLD complicated by\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection at the Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University, from October 2024 to December 2025, were enrolled. Based on liver transient elastography (FibroTouch) results, patients were divided into mild (n = 40), moderate (n = 28), and severe (n = 23) fatty liver groups. All patients received a 14-day HDDT regimen (vonoprazan fumarate 20\u00a0mg\/dose, twice daily; amoxicillin 1.0\u00a0g\/dose, three times daily). The primary outcome measure was changes in liver function (ALT, AST, GGT, ALP) before treatment and at treatment completion; secondary outcome measures were\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication rate and incidence of adverse reactions\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline ALT levels increased with the severity of fatty liver (mild 29.95 \u00b1 16.90 U\/L, moderate 38.24 \u00b1 22.75 U\/L, severe 49.63 \u00b1 19.90 U\/L,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.01). At treatment completion, ALT and AST levels showed an increasing trend in patients with mild and moderate fatty liver but a decreasing trend in patients with severe fatty liver; however, none of the differences were statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). A total of 2 cases (2.2%) experienced transient mild elevation of transaminases (&amp;lt;2 times the upper limit of normal), which resolved spontaneously after drug discontinuation, and no grade 2 or higher drug-induced liver injury occurred. The eradication rates (ITT) in the three groups were 92.50%, 89.29%, and 91.30%, respectively, with no statistically significant difference between groups (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt; 0.05). The total incidence of adverse reactions was 23.08%, mainly mild gastrointestinal symptoms such as bloating and nausea, with no serious adverse events\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      HDDT demonstrates good hepatic safety and high eradication rates in patients with mild to severe MAFLD who have mildly elevated liver enzymes. It can be recommended as a treatment option for\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication in this patient population, but monitoring of liver function changes is advised.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1854790","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:32:37Z","timestamp":1781868757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety of high-dose dual therapy for Helicobacter pylori eradication in patients with varying degrees of metabolic associated fatty liver disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Lingyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Practice, Shougang Hospital of Peking University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1565298","DOI":"10.3389\/fcimb.2025.1565298","article-title":"Overweight and Helicobacter pylori infection: a correlation in metabolic dysfunction-associated fatty liver disease","volume":"15","author":"Chen","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3760\/cma.j.cn501113-20240327-00163","article-title":"Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease (Version 2024)","volume":"32","year":"2024","journal-title":"Zhonghua gan Zang Bing Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3760\/cma.j.cn114798-20241021-00829","article-title":"Guidelines for the diagnosis, treatment and management of metabolic-related fatty liver disease at the primary level","volume":"24","year":"2025","journal-title":"Chin. J. General Pract."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e75677","DOI":"10.7759\/cureus.75677","article-title":"A comprehensive review of pathophysiological link between non-alcoholic fatty liver disease, insulin resistance, and metabolic syndrome","volume":"16","author":"Eudith","year":"2024","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/hep.1840080513","article-title":"Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic","volume":"8","author":"Fr\u00e9neaux","year":"1988","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.cn311367-20220206-00057","article-title":"Sixth Chinese national consensus report on the management of Helicobacter pylori infection (treatment excluded)","volume":"42","year":"2022","journal-title":"Chin. J. Dig."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.3390\/molecules30183825","article-title":"Hepatotoxicity and antimicrobial resistance to amoxicillin and amoxicillin\/clavulanic acid: data analysis from EudraVigilance","volume":"30","author":"Ilaria","year":"2025","journal-title":"Mol. Basel, Switz."},{"key":"B7","doi-asserted-by":"publisher","first-page":"106974","DOI":"10.1016\/j.medcli.2025.106974","article-title":"Helicobacter pylori and gastric disease","volume":"165","author":"Javier","year":"2025","journal-title":"Med. Clinica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11095-019-2582-y","article-title":"Analyzing the mechanisms behind macrolide antibiotic-induced liver injury using quantitative systems toxicology modeling","volume":"36","author":"Jeffrey","year":"2019","journal-title":"Pharm. Research"},{"key":"B9","doi-asserted-by":"publisher","first-page":"107159","DOI":"10.1016\/j.ijantimicag.2024.107159","article-title":"Helicobacter pylori eradication with high-dose proton pump inhibitor-amoxicillin dual therapy: a systematic review and meta-analysis","volume":"63","author":"Jia","year":"2024","journal-title":"Int. Journal Antimicrobial Agents"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e34605","DOI":"10.1097\/MD.0000000000034605","article-title":"Helicobacter pylori infection increases the risk of nonalcoholic fatty liver disease: possible relationship from an updated meta-analysis","volume":"102","author":"Liu","year":"2023","journal-title":"Medicine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.3748\/wjg.v30.i43.4636","article-title":"Prevalence of Helicobacter pylori infection in China from 2014-2023: a systematic review and meta-analysis","volume":"21","author":"Lu","year":"2024","journal-title":"World Journal Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040933","article-title":"Active Helicobacter pylori infection is independently associated with nonalcoholic steatohepatitis in morbidly Obese patients","volume":"9","author":"Michael","year":"2020","journal-title":"J. Clinical Medicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3969\/j.issn.1671-038X.2025.04.01","article-title":"Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease with integrated traditional Chinese and Western medicine","volume":"33","year":"2025","journal-title":"Chin. J. Integr. Traditional Chin. West. Med. Dig."},{"key":"B15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","article-title":"Ten-day Vonoprazan-Amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy","volume":"118","author":"Qian","year":"2023","journal-title":"Am. Journal Gastroenterology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00323","DOI":"10.14309\/ctg.0000000000000323","article-title":"Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"12","author":"Qu","year":"2021","journal-title":"Clin. Translational Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/jir.2023.0162","article-title":"Molecular insights of nonalcoholic fatty liver disease pathogenesis","volume":"44","author":"Reham","year":"2024","journal-title":"J. Interferon Cytokine Research"},{"key":"B18","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1080\/07853890.2022.2031269","article-title":"Multi-Center clinical research collaboration group of sichuan provincial H. pylori scientific group, sichuan provincial medical association; the prospective multiple-centre randomized controlled clinical study of high-dose amoxicillin-proton pump inhibitor dual therapy for H. pylori infection in sichuan areas","volume":"54","author":"Shen","year":"2022","journal-title":"Ann. Medicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jgh3.12852","article-title":"Vonoprazan and high-dose amoxicillin dual therapy for Helicobacter pylori first-line eradication: a single-arm, interventional study","volume":"7","author":"Soichiro","year":"2023","journal-title":"JGH Open An Open Access Journal Gastroenterology Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.gtc.2010.08.007","article-title":"Pharmacologic aspects of eradication therapy for Helicobacter pylori infection","volume":"39","author":"Takahisa","year":"2010","journal-title":"Gastroenterology Clin. N. Am."},{"key":"B21","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.3390\/jcm12093110","article-title":"Expectations for the dual therapy with vonoprazan and amoxicillin for the eradication of H. pylori","volume":"12","author":"Takahisa","year":"2023","journal-title":"J. Clinical Medicine"},{"key":"B22","first-page":"872","article-title":"Efficacy of vonoprazan combined with amoxicillin in the eradication of Helicobacter pylori infection in elderly patients","volume":"32","author":"Wang","year":"2023","journal-title":"J. Gastroenterology Hepatology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"William","year":"2024","journal-title":"Am. Journal Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"655","DOI":"10.14309\/ajg.0000000000002592","article-title":"Ten-day Vonoprazan-Amoxicillin dual therapy vs standard 14-Day bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a multicenter randomized clinical trial","volume":"119","author":"Yan","year":"2024","journal-title":"Am. Journal Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100863","DOI":"10.3748\/wjg.v31.i13.100863","article-title":"Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: proton pump inhibitor and potassium-competitive acid blocker, which's better?","volume":"31","author":"Yang","year":"2025","journal-title":"World Journal Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"19530","DOI":"10.1038\/s41598-022-23746-0","article-title":"Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial","volume":"12","author":"Yu","year":"2022","journal-title":"Sci. Reports"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17562848251354868","DOI":"10.1177\/17562848251354868","article-title":"Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for Helicobacter pylori treatment: a randomized clinical trial","volume":"18","author":"Zhang","year":"2025","journal-title":"Ther. Adv. Gastroenterology"},{"key":"B28","first-page":"214","article-title":"Effect of bismuth quadruple therapy containing amoxicillin and clarithromycin on liver function in patients with Helicobacter pylori infection and concomitant nonalcoholic simple fatty liver","volume":"21","author":"Zhang","year":"2026","journal-title":"China Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"On behalf of Helicobacter pylori study group of Chinese society of gastroenterology. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin. Medical Journal"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Zobair","year":"2023","journal-title":"Hepatology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854790\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T11:32:40Z","timestamp":1781868760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1854790\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":30,"alternative-id":["10.3389\/fphar.2026.1854790"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1854790","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1854790"}}